


# CLINICAL TRIAL

NCT02065011



Low vision

## An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat® in Patients With Usher Syndrome Type 1B

Rare Eye Disease concerned by the trial :  
Usher Syndrome

Status of the trial : enrolling by invitation  
Orphan drug recognition : N/A

**Inclusion criteria :** Provide signed and dated written informed consent (and if appropriate assent) and any locally required authorization eg, Health Insurance Portability and Accountability Act (HIPAA).  
Must have been enrolled in Protocol TDU13600  
Must have received a subretinal injection of UshStat®

**Exclusion criteria :** Did not receive UshStat® as part of the TDU13600 protocol



Inclusion opening date : 27/11/2015



Inclusion closing date (previsional) : 20/03/2035

Children



Adults



### Within ERN-EYE members



Principal location of the trial :

**CHNO des XV XX**  
28 rue de Charenton  
75012 Paris  
France

[Contact details](#)



Principal investigator name :


Pr José Alain Sahel



Other investigators :

Dr Saddek Mohand Saïd  
Pr Isabelle Audo

**CHNO des XV XX**



Funder type : Drug company - Industry

[More informations](#)